Black Rose Industries Ltd Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 3- The company anticipates revenue growth of 10-30% in the current year but will provide updates on a quarter-to-quarter basis as visibility improves.
- Q4 FY23 saw improving margins and the company expects this trend to continue with better results and opportunities ahead.
- Export volumes are being focused on due to higher realizations compared to the domestic market.
- Manufacturing revenues are expected to pick up in coming quarters, moving towards parity with distribution revenues.
- A fourfold increase in sales of N-methylol acrylamide is expected next quarter following customer approvals.
- Ongoing R&D and feasibility studies with Japanese, US, and European partners may add future revenue streams.
- Volume-wise, FY23 volumes for acrylamide were slightly lower than FY22, but Q4 volumes increased significantly.
- Overall, the mood within the organization is positive with expectations of stabilization, market improvements, and profitability growth.
See what Black Rose Industries Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No specific information or announcements were made regarding current or future fundraising through debt or equity in the transcript.
- The company is in a strong financial position with zero long-term debt and a very low debt-equity ratio of 0.02.
- Cash flow from operations is strong at 225 million, supporting operational needs.
- Any future developments, including potential fundraising activities, are under secrecy agreements or not disclosed.
- Management prefers to share information proactively when appropriate and feasible, especially in physical meetings like AGMs.
- No explicit plans for debt or equity fundraising were indicated during this webinar.
See what Black Rose Industries Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Ongoing and upcoming projects include R&D on ceramic binders, acrylic dispersants (polycarboxylates and polyacrylamide solids).
- Feasibility study underway for a specialty chemical project in collaboration with a Japanese company.
- Discussions ongoing for two potential toll manufacturing projects with US and European companies; details under secrecy agreements.
- Manufacturing business CapEx remains largely unchanged at approximately ₹58 crores.
- Expansion potential exists: current acrylamide liquid capacity is 32,000 tons, with room to expand by another 60,000 tons.
- PAM Solid project is under R&D for about a year with construction pending post-completion; technology being developed in-house.
- Expected CapEx and construction timelines not disclosed due to confidentiality.
Track Black Rose Industries Ltd — get its next earnings analysis in your feed
Margin guidance
Category 1- The company expects revenue growth of 10-30% in the year but will provide updates quarter-to-quarter rather than giving full-year guidance due to high uncertainty.
- EBITDA margins are currently in double digits and are expected to improve further with better procurement and inventory management.
- Margin improvements have already begun, especially on acrylamide products, with doubling of margins seen in the last quarter.
- The company is cautiously maintaining low inventory levels to benefit from raw material price falls and better margin stability.
- Earnings growth outlook is positive but incremental and gradual, with better profitability expected as market conditions stabilize and costs reduce.
- EPS for FY23 was 1.29, and with improved margins and volumes, future EPS is expected to improve correspondingly.
- Management prefers to update on earnings outlook quarter-wise to avoid misleading information due to market volatility.
Order book
- The transcript does not explicitly mention details about the current or expected order book or pending orders.
- There is no direct disclosure regarding the size, value, or status of order books.
- Discussions focus more on financial performance, R&D projects (like PAM Solid), capacity, and market outlook.
- Confidentiality and secrecy agreements restrict sharing certain operational details, such as toll manufacturing plant specifics.
- Management emphasizes cautious optimism with improving margins and stabilization in markets but refrains from giving specific future orders or order book guidance.
- Future developments and significant updates will be shared in subsequent webinars or physical meetings when available.
How does Black Rose Industries Ltd rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Black Rose Industries Ltd rank in Chemicals & Petrochemicals?
Compare Black Rose Industries Ltd against every Chemicals & Petrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Black Rose Industries Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…